Business Context and Reporting Period
This Form 8-K Current Report was filed by Privia Health Group, Inc. (PRVA) on August 12, 2026. The report discloses corporate governance changes regarding the Board of Directors, specifically the election of a new director and committee appointments effective September 1, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Election: The Board elected Opella Ernest, M.D., as a Class III director, effective September 1, 2026.
- Committee Appointment: Dr. Ernest was appointed to the Compliance Committee, effective September 1, 2026.
- Independence: The Board determined Dr. Ernest to be independent under Nasdaq Stock Market rules.
- Compensation: Dr. Ernest will receive an annual cash retainer and an annual equity grant of restricted stock units (RSUs) with a grant date fair market value of $200,000. The initial grant will be pro-rated based on the time served until the next annual meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document confirms there are no undisclosed arrangements or material interest transactions involving Dr. Ernest requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of Dr. Ernest's board service (September 1, 2026).
- Confirm the pro-rated calculation of the initial $200,000 RSU grant based on the timing of the next annual meeting.
- Review the attached Press Release (Exhibit 99.1) for additional context on the Board's strategic rationale.
- Check subsequent filings for the formal execution of the RSU award agreement.